Isoquercetin
- Generic Name
- Isoquercetin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20O12
- CAS Number
- 482-35-9
- Unique Ingredient Identifier
- 6HN2PC637T
- Background
Isoquercetin has been used in trials studying the treatment of Kidney Cancer, Renal cell carcinoma, Advanced Renal Cell Carcinoma, Thromboembolism of Vein in Pancreatic Cancer, and Thromboembolism of Vein VTE in Colorectal Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
AB Science: Revenues for the first half of 2024 and update
AB Science reports financial results for H1 2024, including a 59.5% reduction in operating deficit to €3.6 million. Key clinical updates include ongoing re-examinations of masitinib for ALS by EMA and Health Canada, positive phase 2 results for masitinib in Covid-19, and updates on the AB8939 microtubule program. The company also strengthened intellectual property for masitinib in mastocytosis and completed a €5 million capital increase.
Related Clinical Trials:
Revenues for the first half of 2024 and update on AB Science's activities
AB Science reports H1 2024 financial results, ongoing re-examination of masitinib MAA for ALS by EMA and Health Canada, updates on masitinib developments in MS and Covid-19, and positive phase 2 results for masitinib in Covid-19. The company also strengthens IP for masitinib in mastocytosis and updates on AB8939 microtubule program.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath